EUVIMEDEUVIMED entdecken
Kohortenstudie

Association Between Use of Fluoroquinolones and Risk of Mitral or Aortic Valve Regurgitation: A Nationwide Cohort Study

Yaa-Hui Dong iD, Jiun-Ling Wang iD, Chia-Hsuin Chang, Jou-Wei Lin, Yu-An Chen, Chun-Yu Chen, Sengwee Toh iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3084 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Yaa-Hui Dong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Fluoroquinolones, Aortic Valve. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biological plausibility suggests that fluoroquinolones may lead to mitral valve regurgitation or aortic valve regurgitation (MR/AR) through a collagen degradation pathway. However, available real‐world studies were limited and yielded inconsistent findings. We estimated the risk of MR/AR associated with fluoroquinolones compared with other antibiotics with similar indications in a population‐based cohort study. We identified adult patients who initiated fluoroquinolones or comparison antibiotics from the nationwide Taiwanese claims database. Patients were followed for up to 60 days after cohort entry. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of MR/AR comparing fluoroquinolones to comparison antibiotics after 1:1 propensity score (PS) matching. All analyses were conducted by type of fluoroquinolone (fluoroquinolones as a class, respiratory fluoroquinolones, and non‐respiratory fluoroquinolones) and comparison antibiotic (amoxicillin/clavulanate or ampicillin/sulbactam, extended‐spectrum cephalosporins). Among 6,649,284 eligible patients, the crude incidence rates of MR/AR ranged from 1.44 to 4.99 per 1,000 person‐years across different types of fluoroquinolones and comparison antibiotics. However, fluoroquinolone use was not associated with an increased risk in each pairwise PS‐matched comparison. HRs were 1.00 (95% CI, 0.89–1.11) for fluoroquinolones as a class, 0.96 (95% CI, 0.83–1.12) for respiratory fluoroquinolones, and 0.87 (95% CI, 0.75–1.01) for non‐respiratory fluoroquinolones, compared with amoxicillin/clavulanate or ampicillin/sulbactam. Results were similar when fluoroquinolones were compared with extended‐spectrum cephalosporins (HRs of 0.96, 95% CI, 0.82–1.12, HR, 1.05, 95% CI, 0.86–1.28, and HR, 0.88, 95% CI, 0.75–1.03, respectively). This large‐scale cohort study did not find a higher risk of MR/AR with different types of fluoroquinolones in the adult population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoroquinolonesAortic ValveAdultHumansCohort StudiesSulbactamAnti-Bacterial AgentsAmoxicillin-Potassium Clavulanate CombinationAmpicillinCephalosporins

Substanzen

FluoroquinolonessultamicillinSulbactamAnti-Bacterial AgentsAmoxicillin-Potassium Clavulanate CombinationAmpicillinCephalosporins

Autor:innen und Institutionen

  • Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Institute of Public Health, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Institute of Hospital and Health Care Administration, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
  • Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

ORCID-Profile: Yaa-Hui Dong, Jiun-Ling Wang, Sengwee Toh

Förderung

  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Dong, Y. H., Wang, J. L., Chang, C. H., Lin, J. W., Chen, Y. A., Chen, C. Y., & Toh, S. (2024). Association Between Use of Fluoroquinolones and Risk of Mitral or Aortic Valve Regurgitation: A Nationwide Cohort Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3084

Vancouver

Dong YH, Wang JL, Chang CH, Lin JW, Chen YA, Chen CY, et al. Association Between Use of Fluoroquinolones and Risk of Mitral or Aortic Valve Regurgitation: A Nationwide Cohort Study. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3084

BibTeX
@article{Dong2024,
  author = {Dong, Yaa-Hui and Wang, Jiun-Ling and Chang, Chia-Hsuin and Lin, Jou-Wei and Chen, Yu-An and Chen, Chun-Yu and Toh, Sengwee},
  title = {Association Between Use of Fluoroquinolones and Risk of Mitral or Aortic Valve Regurgitation: A Nationwide Cohort Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3084}
}
Kostenlos starten →